Viking Therapeutics Inc (VKTX)

Viking Therapeutics (VKTX) stock falls 3.81% to $15.38 following updates from competitors regarding their programs. However, considering the share price drop, Oppenheimer analyst Jay Olson thinks that not only is the decline unmerited, but that developments elsewhere bode well for Viking’s pipeline. Olson really does think the shares are undervalued.

https://finance.yahoo.com/news/oppenheimer-predicts-140-rally-3-001454780.html

VKTX's stock fell 18.22% following Eli Lilly's impressive mid-stage trial results for its next-generation obesity therapy, achieving a best-in-class mean weight loss of 24.2% at 48 weeks. This posed competitive implications for the company's product VK2735, which was previously estimated to reach its sales peak of over $6 billion as the potential best-in-class weight-loss treatment.

https://www.fool.com/investing/2023/06/27/why-viking-therapeutics-is-plunging-today/

VKTX's stock fell 11.08% due to some information about a pair of therapies to treat obesity and metabolic disorders like diabetes of the company. There are some arguments against buying VKTX. Flubbing a clinical trial or getting rebuffed by regulators would be the most significant. Hypothetically speaking, if anti-obesity medicines on the market turned out to be less safe or effective than initially thought, there would doubtlessly be negative spillover to Viking. There is also the risk of established competitors entrenching themselves firmly in the markets. Businesses like Novo Nordisk, Eli Lilly, Pfizer, and others are going to have massive advantages in securing and retaining market share relative to Viking. They're simply much larger and far more experienced in the commercialization process, and they all will have a very long head start as their products are either already on the market or well on their way.

https://www.fool.com/investing/2023/06/20/after-blasting-off-881-in-1-year-is-viking-still/